Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment

Aleksandra P. Vidisheva, James Wang, Tanya M. Spektor, Jacob D. Bitran, Jose Lutzky, Imad A. Tabbara, Joseph Z. Ye, Sikander Ailawadhi, Laura V. Stampleman, Ronald G. Steis, Mehdi M. Moezi, Regina A. Swift, Tina M. Maluso, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, James R. Berenson

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Objective: Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. Methods: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. Results: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. Conclusion: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Apr 28 2017
Externally publishedYes

Keywords

  • Bortezomib
  • Multiple myeloma
  • Peripheral neuropathy
  • Retreatment
  • Retrospective

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment'. Together they form a unique fingerprint.

  • Cite this

    Vidisheva, A. P., Wang, J., Spektor, T. M., Bitran, J. D., Lutzky, J., Tabbara, I. A., Ye, J. Z., Ailawadhi, S., Stampleman, L. V., Steis, R. G., Moezi, M. M., Swift, R. A., Maluso, T. M., Udd, K. A., Eshaghian, S., Nassir, Y., & Berenson, J. R. (Accepted/In press). Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer, 1-8. https://doi.org/10.1007/s00520-017-3732-6